Foamix Pharmaceuticals Ltd. (FOMX) EPS Estimated At $-0.45 on May, 8

April 16, 2018 - By Patrick Harkless

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)’s quarterly earnings will be announced On May, 8., as reported by RTT. EPS of $-0.45 is 15.38 % down from 2017’s $-0.39 EPS. -2.17 % EPS growth is what Wall Street’s predicts after $-0.46 reported EPS last quarter. On during the last trading session the stock increased $0.14 or 2.66%, reaching $5.41.Currently Foamix Pharmaceuticals Ltd. is downtrending after 13.02% change in last April 17, 2017. FOMX has 147,039 shares volume. The stock underperformed the S&P 500 by 24.57%.

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Ratings Coverage

In total 2 analysts cover Foamix Pharma (NASDAQ:FOMX). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 3 are the (NASDAQ:FOMX)’s analyst reports since November 29, 2017 according to StockzIntelligence Inc. The company rating was initiated by Guggenheim on Tuesday, December 5. In Friday, January 5 report H.C. Wainwright maintained the stock with “Buy” rating. On Wednesday, November 29 the firm has “Buy” rating given by H.C. Wainwright.

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular, rosacea, and other skin conditions in the United States, Germany, and France.The company has $203.15 million market cap. The Company’s lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus.Currently it has negative earnings. The firm is also developing FMX103, a version of its minocycline foam FMX101, which is in Phase II clinical trial for the treatment of rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash.

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.